Agios Pharmaceuticals
AGIO
159 hedge funds and large institutions have $1.62B invested in Agios Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 71 increasing their positions, 49 reducing their positions, and 22 closing their positions.
58% more call options, than puts
Call options by funds: $16.5M | Put options by funds: $10.4M
45% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 49
2.45% more ownership
Funds ownership: 105.74% → 108.2% (+2.5%)
1% less capital invested
Capital invested by funds: $1.64B → $1.62B (-$16.6M)
5% less funds holding
Funds holding: 168 → 159 (-9)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$23.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.3M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$14.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.86M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$10M |
| 2 |
JP Morgan Chase
New York
|
-$8.56M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$7.71M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.5M |
| 5 |
Goldman Sachs
New York
|
-$5.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QC
176
Quent Capital
New York
| – | -$1K | -23 | Closed |
|
177
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$197 | -7 | -47% |
|
|
C
178
Covestor
London,
United Kingdom
| – | -$56 | -2 | -29% |
|
|
SFG
179
Steward Financial Group
Colleyville,
Texas
| – | +$141 | +5 | New |
|
AGIO Hedge Fund Activity: Q4 2022 in Review
159 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2022, worth a combined $1.62B — down 1% from $1.64B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AGIO and 16 opened new positions — a net loss of 6 holders — while 49 trimmed existing stakes and 71 added.
The largest buyer was Armistice Capital, adding an estimated $23.3M. The largest seller was First Trust Advisors, cutting an estimated $10M.
- 159 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2022, down from 168 in Q3 2022.
- Funds reported $1.62B of Agios Pharmaceuticals stock for Q4 2022, down 1% quarter-over-quarter.
- 16 funds opened new Agios Pharmaceuticals positions in Q4 2022 and 22 closed out, a net change of -6 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2022 was Armistice Capital, an estimated $23.3M added.
- The largest Agios Pharmaceuticals seller in Q4 2022 was First Trust Advisors, an estimated $10M sold.
Based on aggregated 13F filings for Q4 2022.